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Abbasoglu et al published a narrative review concerning the
use of fish oil–containing lipid emulsions in adult parenteral
nutrition (PN).1 We wholeheartedly agree with the authors
when they state that “high-quality and adequately powered
RCTs are necessary” and “well-conducted meta-analyses
can be key to demonstrating positive or negative effects.”
However, we disagree with other aspects of their review,
particularly assertions of a lack of evidence in favor of
using fish oil–containing lipid emulsions rather than more
traditional lipid formulations.
The authors mentioned that 4 meta-analyses show a
significant clinical benefit for fish oil–containing lipid emul-
sions. There are at least 4 additional meta-analyses that
have shown such benefits,2-5 so 8 meta-analyses have results
significantly in favor of fish oil in adult PN, but 2 show no
significant differences.6,7 Both those showing no significant
differences included few trials (6 in each case) and very few
(<400) patients.6,7 Moreover, when one was updated with
additional studies, it found significantly fewer infectious
complications and shorter length of hospital stay in patients
given fish oil–containing lipid emulsions.8
Abbasoglu et al stated that “key medical societies are
challenged to provide recommendations” for lipid emulsion
choice, and that ASPEN. does not recommend one lipid
emulsion over another. This is disingenuous, as ASPEN.
states, “When these alternative IVFEs (SMOF [soybean
oil, MCT, olive oil, and fish oil emulsion], MCT [medium
chain triglycerides], OO [olive oil], and FO [fish oil]) become
available in the United States, based on expert opinion,
we suggest that their use be considered in the critically ill
patient who is an appropriate candidate for PN.”9 Moreover,
after assessing the evidence base, the European Society for
Parenteral and Enteral Nutrition (ESPEN) recommends
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fish-oil use in many ICU, surgical, and cancer patients in
2009 and 2017 guidelines.10-14
When making an assessment, the choice of (1) what
to include and (2) how to process these data are 2 key
variables:15 (1) Abbasoglu et al used broad inclusion criteria
(34 studies were included), only excluding studies not in
English, of children, or if only enteral nutrition (EN) was
used. However, a large number of RCTs were excluded by
Abbasoglu et al for reasons that are not clear, but instead
they include retrospective/observational studies, which con-
stitute a lower level of evidence. Moreover, many of the
studies included “off-label” use of fish oil as the only
lipid source. (2) Abbasoglu et al performed a nonsystem-
atic narrative review, considered to be a fairly weak level
of evidence within the evidence-based medicine hierarchy,
whereas meta-analyses are among the most powerful meth-
ods available. Given the weight of evidence from meta-
analyses and international guidelines, are the contradictory
conclusions from Abbasoglu et al appropriate? Also, the
reason given for not doing a meta-analysis was “the low
quality of most studies and the substantial heterogeneity,”
but they then used data from these same “low-quality”
studies to reach their conclusions.
In conclusion, we agree with Abbasoglu et al that further
large-scale RCTs are needed, but we disagree that there is
little benefit to using fish oil. The weight of evidence, sup-
ported by international guidelines, indicates clinical benefits
for using fish oil–enriched PN in adult patients.
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